Innate Pharma, S.A.
9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
7
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 30, 2026The maintenance fee for Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders (US 9,067,997) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,732,131 | Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor In force · From the USPTO record | In force | From the USPTO record | |
| US 10,160,810 | Monoclonal antibodies against NKG2A In force · From the USPTO record | In force | From the USPTO record | |
| US 7,803,376 | Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using NK Cell Potentiating Compounds In force · High confidence | In force | High confidence | |
| US 8,993,319 | Monoclonal antibodies against NKG2A In force · From the USPTO record | In force | From the USPTO record | |
| US 8,388,970 | Kir-Binding Agents and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 8,222,376 | Kir-Binding Agents and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 9,447,185 | Compositions and Methods for Treating Proliferative Disorders In force · High confidence | In force | High confidence | |
| US 9,067,997 | Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 8: 9 patents in force now held by others · 12 lapsed for an unpaid fee · 10 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 abandoned · 20 no status recorded